NCT04926584Recruiting
Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option
Prospective Trial of Immunotherapy Prior to Resection, Definitive Chemo-radiotherapy, or Palliative Therapy in Patients With Locally Advanced or Oligometastatic Non-small Cell Lung Cancer Without a Primary Curative Option
Source: ClinicalTrials.gov · Last updated 16 Aug 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In a certified lung- cancer center, patients with NSCLC and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons. For these patients, the multidisciplinary tumor board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically including PET-CT if indicated. After review of the MDB, patients receive either definitive curative treatment or palliative treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 9 Jun 2021
- Start date
- 15 Dec 2017
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Klinikum Esslingen
- Diseases
- Lung cancer
- NCT number
- NCT04926584
What you commit to
- Study type: Observational
- Planned participants: 50
- From 15 Dec 2017 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- primary resectability
- primary definitive chemoradiotherapy feasible
Who the study is looking for
- newly diagnosed NSCLC
- histologically or cytologically proven
- stage III - IVA (oligometastatic) by complete staging
- ECOG 0-2
- life expectancy 3 months
- ability to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Klinikum Esslingen Coordinator of this site? Confirm its status | Esslingen am Neckar | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.